| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
JNK3 (IC50 = 87 nM nM); JNK2 (IC50 = 360 nM); JNK1 (IC50 = 390 nM)
IQ-1S targets c-Jun N-Terminal Kinases (JNKs), specifically JNK1, JNK2, and JNK3. It is a selective JNK3 inhibitor with IC50 values of 390 nM for JNK1, 360 nM for JNK2, and 87 nM for JNK3. It has Kd values of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively. By inhibiting JNK, it modulates inflammatory and stress responses. |
|---|---|
| ln Vitro |
Compound IQ-1S is a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Evaluation of IQ-1S' impact on human PBMCs' LPS-induced cytokine production. LPS (200 ng/mL) consistently induces five of the 12 cytokines examined (IL-1α, IL-1β, IL-6, IL-10, and TNF-α) in PBMCs when compared to DMSO-treated control cells. 20 M IQ-1S significantly reduces the production of each of these cytokines. TNF-α production is completely prevented by IQ-1 (>99%), IL-1α, IL-1β, and IL-10 levels are all reduced by 85%, and IL-6 production is reduced by 33%[1].
IQ-1S is a potent, highly specific JNK inhibitor with IC50 values of 390 nM, 360 nM, and 87 nM for JNK1, JNK2, and JNK3, respectively. It does not inhibit other kinases that represent potential targets for RA treatment, including GSK-3β, JAK2, JAK3, PI3Ks, Btk, and IKK-2. It is a noncytotoxic inhibitor of pro-inflammatory cytokines (IL-1α, IL-1β) in human and murine monocytes/macrophages. |
| ln Vivo |
The serum exposure of the drug is also good when given to mice via intraperitoneal injection at doses of 12.5 and 30 mg/kg of IQ-1S (the sodium salt of IQ-1S), with AUC0-12h values of 2.9 and 7.4 μM/h, respectively[1].
IQ-1S inhibits delayed-type hypersensitivity in mice. Its ability to inhibit JNK and reduce pro-inflammatory cytokine production makes it a potential therapeutic agent for inflammatory diseases such as rheumatoid arthritis. Its high level of specificity for JNK suggests it may have a favorable safety profile. |
| Enzyme Assay |
The primary in vitro assays for IQ-1S include JNK kinase activity assays, where the enzyme is incubated with a substrate and the compound, and the phosphorylation of the substrate is measured. The IC50 values for JNK1, JNK2, and JNK3 are determined from dose-response curves. Its selectivity over other kinases is assessed in similar assays.
|
| Cell Assay |
Human PBMCs are plated in 96-well plates at a density of 2×105 cells/well in culture medium supplemented with 3% (v/v) endotoxin-free FBS. Pretreatment of PBMCs with 20 μM IQ-1S or DMSO for 30 min is followed by the addition of 200 ng/ml LPS for 24 h. A human cytokine MultiAnalyte ELISArray Kit is used to analyze different cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, interferon (IFN)-γ, TNF-α, and granulocyte-macrophage colony-stimulating factor) in PBMC supernatants[1].
Cellular assays for IQ-1S involve treating immune cells, such as monocytes or macrophages, with the compound and measuring its effects on JNK signaling and cytokine production. The inhibition of JNK phosphorylation and downstream targets is assessed by Western blot. The production of pro-inflammatory cytokines, such as IL-1α and IL-1β, is measured by ELISA. |
| Animal Protocol |
Mice: For in vivo analysis, BALB/c mice (15–20 animals per group) are given 12.5 or 30 mg/kg i.p. doses of IQ-1S (the sodium salt of IQ-1), and the mice are sacrificed at different intervals after compound administration. For quantification, mouse serum samples spiked with known concentrations of IQ-1S (0.1–20 μM) are used to create a calibration curve, and a linear dependence of the peak area with IQ-1S concentration is discovered (correlation coefficient r=0.997). The linear trapezoidal method is used to calculate the area under the serum concentration-time curve (AUC0-12h) up to the last concentration that was measured[1].
In vivo animal experiments for IQ-1S have been conducted using the delayed-type hypersensitivity model in mice. The compound was administered to mice, and its effects on the hypersensitivity response were assessed. Its efficacy in this model supports its potential as an anti-inflammatory agent. |
| ADME/Pharmacokinetics |
IQ-1S has a molecular weight of 247.25 g/mol and a molecular formula of C15H9N3O. It is a small molecule that is typically used as a research reagent. It is a potent and selective JNK3 inhibitor with IC50 values of 390 nM, 360 nM, and 87 nM for JNK1, JNK2, and JNK3, respectively.
|
| Toxicity/Toxicokinetics |
The toxicological profile of IQ-1S is not extensively detailed in the provided sources. It is described as a noncytotoxic inhibitor, suggesting a favorable safety profile. As a research compound, it is not intended for human use. Standard safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
IQ-1S is a potent and selective JNK inhibitor with a preference for JNK3. It has IC50 values of 390 nM for JNK1, 360 nM for JNK2, and 87 nM for JNK3. It inhibits delayed-type hypersensitivity in mice and is a noncytotoxic inhibitor of pro-inflammatory cytokines. It is available from various chemical suppliers for research purposes.
|
| Molecular Formula |
C15H9N3O
|
|---|---|
| Molecular Weight |
247.2515
|
| Exact Mass |
247.074
|
| Elemental Analysis |
C, 72.87; H, 3.67; N, 16.99; O, 6.47
|
| CAS # |
23146-22-7
|
| Related CAS # |
23146-22-7
|
| PubChem CID |
619002
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
511.8±43.0 °C at 760 mmHg
|
| Flash Point |
263.3±28.2 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.774
|
| LogP |
2.47
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
19
|
| Complexity |
361
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=NC1C2=C([H])C([H])=C([H])C([H])=C2C2C=1N([H])C1=C([H])C([H])=C([H])C([H])=C1N=2
|
| InChi Key |
YSYIWCNPSZNNKW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H9N3O/c19-18-14-10-6-2-1-5-9(10)13-15(14)17-12-8-4-3-7-11(12)16-13/h1-8,17H
|
| Chemical Name |
11-nitroso-10H-indeno[1,2-b]quinoxaline
|
| Synonyms |
IQ-1S
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~16.7 mg/mL (~67.4 mM)
Ethanol: ~1 mg/mL (~4.0 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.67 mg/mL (6.75 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0445 mL | 20.2224 mL | 40.4449 mL | |
| 5 mM | 0.8089 mL | 4.0445 mL | 8.0890 mL | |
| 10 mM | 0.4044 mL | 2.0222 mL | 4.0445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
